Boehringer Ingelheim Press Releases

Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia

Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes

Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status

New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism

Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX®

FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems

Boehringer Ingelheim and the EFSD call for grant applications in diabetes research

Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog

Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves

Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session